Every material Form 8-K Greenwich LifeSciences, Inc. has filed with the SEC since February 20, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Greenwich LifeSciences, Inc. dismissed RBSM LLP as its independent registered public accounting firm and engaged MaloneBailey LLP to audit its financial statements for the year ending December 31, 2025. RBSM's reports on the 2024 and 2023 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing states there were no disagreements with RBSM. The filing notes material weaknesses in internal control over financial reporting disclosed in prior 10-K and 10-Q reports, which shareholders may want to monitor under the new auditor.
Audit committee approved the change on July 19, 2025; RBSM was informed it would be dismissed effective immediately.
RBSM's audit reports for fiscal 2024 and 2023 had no adverse opinion, disclaimer, or qualification.
The company cites material weaknesses in internal control over financial reporting in its 2024 and 2023 10-K reports and its 2024 and March 31, 2025 10-Q reports.
RBSM's letter to the SEC, dated July 22, 2025, is filed as Exhibit 16.1.
On June 13, 2024, Greenwich LifeSciences agreed to sell 174,825 common shares to its CEO, Snehal Patel, in a private placement for approximately $2.5 million in gross proceeds before offering expenses. The shares are restricted, carry no registration rights, and are expected to close on June 18, 2024. The company plans to use the net proceeds for clinical development and working capital, and the sale adds new shares to the outstanding count.
174,825 shares of common stock priced at $14.30 per share, the Nasdaq official closing price on June 12, 2024
Gross proceeds of approximately $2.5 million before offering expenses
Closing expected June 18, 2024, subject to customary closing conditions
Shares are restricted securities with no registration rights, sold under Section 4(a)(2) and/or Rule 506
Greenwich LifeSciences dismissed MaloneBailey LLP as its independent registered public accounting firm and engaged RBSM LLP to audit its financial statements for the year ended December 31, 2023. The filing states that MaloneBailey's reports for 2021 and 2022 contained no adverse opinion, disclaimer, or qualification, but notes material weaknesses in internal control over financial reporting disclosed in prior filings. The change is administrative in nature, though the disclosed material weaknesses are relevant to shareholders.
Audit committee approved the dismissal of MaloneBailey LLP and the engagement of RBSM LLP on February 14, 2024
MaloneBailey was informed of its dismissal on February 15, 2024, effective immediately
MaloneBailey's reports for 2021 and 2022 had no adverse opinion, disclaimer, or qualification
Material weaknesses in internal control were disclosed in the 2022 and 2021 Form 10-K filings and in 2023 Form 10-Q filings; no disagreements with MaloneBailey are reported
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Greenwich LifeSciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →